Evommune (EVMN) Operating Expenses (2024 - 2026)

Evommune (EVMN) has 3 years of Operating Expenses data on file, last reported at $24.0 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $24.0 million, up 32.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $95.0 million (changed N/A YoY), and the FY2025 annual result was $94.1 million, up 22.15% from the prior year.
• Operating Expenses fell to $24.0 million in Q1 2026 per EVMN's latest filing, from $29.7 million in the prior quarter.
• Over five years, Operating Expenses peaked at $29.7 million in Q4 2025 and troughed at $16.5 million in Q3 2024.
• A 3-year average of $22.2 million and a median of $22.4 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2025 and 2026: Operating Expenses soared 41.24% in 2025, then jumped 32.84% in 2026.
• A 3-year view of Operating Expenses shows it stood at $21.5 million in 2024, then jumped by 38.51% to $29.7 million in 2025, then fell by 19.39% to $24.0 million in 2026.
• Business Quant data shows EVMN's Operating Expenses at $24.0 million in Q1 2026, $29.7 million in Q4 2025, and $23.3 million in Q3 2025.